The Limners and Bards Limited (LAB)
Unaudited financials for the nine months ended July 31, 2024:
The Limners and Bards Limited (LAB) for the nine months ended July 31, 2024, reported an 18% decrease in Operating revenue totaling $752.80 million compared to $913.50 million in the corresponding period last year. Operating revenue for the third quarter also had an 18% decrease to close at $307.20 million compared to $374.35 million for the comparable quarter of 2023.
Cost of operating revenue amounted to $468.26 million (2023: $598.72 million), this represents a decrease of 22% year over year. Consequently, gross profit decreased by 10% to $284.54 million compared to $314.78 million for the nine months ended July 31, 2023. The company booked gross profit of $104.13 million for the third quarter versus $122.14 million reported for the similar quarter of 2023.
Selling and distribution expenses decreased by 50% to close at $1.23 million (2023: $2.48 million), while administrative expenses decreased by 18% from $255.87 million in 2023 to $209.61 million in the period under review. As a result, total operating expenses for the nine months ended July 31, 2024, amounted to $210.84 million, an 18% decrease relative to $258.35 million reported in 2023.
Profit before net finance cost and taxation for the nine months ended July 31, 2024, amounted to $76.06 million, a 35% increase relative to $56.43 million reported in 2023. Profit before net finance cost and taxation for the third quarter amounted to $29.89 million (2023: $34.10 million). Net finance income totalled $7.37 million, increasing from the corresponding period last year. (2023: cost of $8,901).
Profit before taxation for the nine months ended July 31, 2024, amounted to $83.45 million, a 48% increase relative to $56.38 million reported in 2023. Profit before taxation for the third quarter amounted to $34.11 million (2023: $36.52 million).
Tax credit for the nine months ended July 31, 2024, had a 76% decrease to reach $141,425 (2023: $593,994) . Net profit for the nine months amounted to $83.59 million, a 47% increase from the $56.97 million reported in 2023. For the third quarter, Net profit was $34.13 million (2023: $36.68 million).
Consequently, Earnings Per Share for the nine months amounted to $0.09 (2023: EPS: $0.06), while Earnings Per Share for the quarter totaled $0.04 (2023: EPS: $0.04). The twelve-month trailing EPS was $0.09, and the number of shares used in these calculations was 945,690,252.
Notably, LAB’s stock price closed the trading period on September 15, 2024, at a price of $1.41 with a corresponding P/E ratio of 15.89x.
Balance Sheet Highlights
The company’s assets totalled $1.10 billion (2023: $941.22 million). This increase was attributable to ‘Content Asset’ which amounted to $75.43 million for the nine months of 2024. Additionally, ‘Property, Plant and Equipment’ also contributed to the rise in total assets equating to $92.39 million for the nine months ended July 31, 2024 (2023: $60.08 million).
Shareholder’s equity was $681.46 million (2023: $597.53 million), representing a book value per share of $0.72 (2023: $0.63).
Disclaimer:
Analyst Certification – The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer(s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this research report.
Company Disclosure – The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.
